Pharmacopeia Announces Agreement With Columbia University and Cold Spring Harbor
Pharmacopeia Drug Discovery, Inc. announced that it has entered into an amended license agreement with Columbia University and Cold Spring Harbor Laboratory covering Pharmacopeia’s core tagging technology used in its proprietary combinatorial chemistry encoding technology, Encoded Combinatorial Libraries on Polymeric Support, or ECLiPS(R). Pharmacopeia also announced that it has resolved a prior dispute with Columbia and Cold Spring Harbor regarding the payment of certain royalties under the pre-existing license agreement among the parties.
“We are very pleased to continue this important relationship with both Columbia University and Cold Spring Harbor,” said Les Browne, Ph.D., president and chief executive officer of Pharmacopeia. “As Pharmacopeia expands its drug discovery and development we believe that this renewed commitment from all parties will result in advancements in Pharmacopeia’s internal pipeline as well as our partnered programs.”
Pharmacopeia Drug Discovery, Inc. ( http://www.pharmacopeia.com ) is a biopharmaceutical company focused on the creation of new small molecule therapeutics to address significant unmet medical needs. Using proprietary technologies and processes, Pharmacopeia discovers and develops novel drug candidates for development internally as well as with strategic partners. The company is advancing multiple internal programs – focused primarily on immunobiology and immunological diseases – to validation in clinical trials. Pharmacopeia’s later stage portfolio currently comprises multiple partnered programs that have been advanced into human clinical trials with further programs in late-stage pre-clinical development. Beyond these, the company has developed a pipeline of approximately 40 partnered and internal programs in discovery that are expected to drive the company’s clinical portfolio in the future.
